Kari Honeycutt
Family · Corbin, KYNPI 1942642509
Payments from drug & device makers
Across 230 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$666
- Lilly USA, LLC$434
- Astellas Pharma US Inc$427
- UCB, Inc.$410
- Sunovion Pharmaceuticals Inc.$385
- Amgen$228
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,67695%
- Education$1875%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 25 | $666 |
| Lilly USA, LLC | 32 | $434 |
| Astellas Pharma US Inc | 25 | $427 |
| UCB, Inc. | 25 | $410 |
| Sunovion Pharmaceuticals Inc. | 32 | $385 |
| Amgen | 12 | $228 |
| AbbVie | 13 | $187 |
| Teva Pharmaceuticals USA, Inc. | 6 | $166 |
| Mylan Specialty L.p. | 9 | $157 |
| Johnson & Johnson | 5 | $81 |
| AstraZeneca | 5 | $78 |
| Boehringer Ingelheim | 6 | $74 |
| Jazz Pharmaceuticals Inc. | 4 | $73 |
| GSK | 4 | $58 |
| Adamas Pharmaceuticals, Inc. | 4 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Pfizer | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Novartis | 2 | $25 |
| SK Life Science, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Medtronic | 1 | $17 |
| Neurelis, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Merck | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Radius Health, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$419
How this compares
$3,864 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 232 | $186,399 |
| EliquisApixaban | 481 | $155,111 |
| LinzessLinaclotide | 236 | $134,697 |
| OzempicSemaglutide | 117 | $119,441 |
| ForteoTeriparatide | 24 | $108,358 |
| JardianceEmpagliflozin | 251 | $82,863 |
| YupelriRevefenacin | 42 | $63,502 |
| EntrestoSacubitril/Valsartan | 163 | $58,024 |
| Tresiba Flextouch U-200Insulin Degludec | 61 | $43,935 |
| NuplazidPimavanserin Tartrate | 14 | $33,838 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $32,646 |
| Teriparatide | 13 | $28,127 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $25,834 |
| RestasisCyclosporine | 35 | $22,503 |
| LokelmaSodium Zirconium Cyclosilicate | 63 | $21,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $44 | $186,399232 claims |
| AbbVieLinzess, Restasis | $187 | $157,200271 claims |
| PfizerEliquis | $51 | $155,111481 claims |
| Lilly USA, LLCForteo, Trulicity, Mounjaro | $434 | $148,38857 claims |
| Boehringer IngelheimJardiance | $74 | $82,863251 claims |
| Mylan Specialty L.p.Yupelri | $157 | $63,50242 claims |
| NovartisEntresto | $25 | $58,024163 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $58 | $43,60964 claims |
| AstraZenecaLokelma, Farxiga | $78 | $38,25589 claims |
| UCB, Inc.Neupro | $410 | $18,67221 claims |
| Johnson & JohnsonXarelto | $81 | $17,17647 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $52 | $14,25424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.
Other family in Corbin
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.